NEW YORK (GenomeWeb) – OncoCyte said today that its second quarter net loss rose, compared to the same period last year, as it prepares to launch a noninvasive lung cancer diagnostic dubbed DetermaVu.

The liquid biopsy firm's net loss for the three months ended June 30, 2017 was $3.8 million, or $.13 per share, compared to a loss of $2.5 million, or $.10 per share in Q2 2016. The consensus Wall Street estimate was for a loss of $.12 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.